Association of RAMP1 rs7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache

• Published in: Headache Vol. 55; no. 5; pp. 658 - 668
• Main Authors: Cargnin, Sarah, Pautasso, Chiara, Viana, Michele, Sances, Grazia, Mittino, Daniela, Cantello, Roberto, Tassorelli, Cristina, Nappi, Giuseppe, Terrazzino, Salvatore
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.05.2015
• Subjects: Adult; CGRP-related gene; Female; Headache Disorders, Secondary - chemically induced; Headache Disorders, Secondary - diagnosis; Headache Disorders, Secondary - genetics; Humans; Male; medication overuse headache; Middle Aged; migraine; Migraine Disorders - diagnosis; Migraine Disorders - drug therapy; Migraine Disorders - genetics; polymorphism; Receptor Activity-Modifying Protein 1 - genetics; Retrospective Studies; Risk Factors; susceptibility; triptan; Tryptamines - adverse effects; Tryptamines - therapeutic use; medication overuse headache; polymorphism; migraine; susceptibility; CGRP-related gene; triptan
• ISSN: 0017-8748; 1526-4610
• DOI: 10.1111/head.12559

Objectives/Background We herein investigated the role of polymorphisms in calcitonin gene‐related peptide (CGRP)‐related genes looking at the association of rs3781719 (T > C) in the calcitonin gene‐related polypeptide‐alpha (CALCA) gene and of rs3754701 (T > A) and rs7590387 (C > G) at the receptor activity modifying 1 (RAMP1) locus with triptan response in patients with migraine without aura (MwoA). In addition, their role was evaluated as risk factors for transformation of episodic migraine into medication overuse headache (MOH). The CGRP has a central role in the pathogenesis of migraine; however, little information is currently available concerning the role of polymorphisms in CGRP‐related genes as determinants of clinical response to anti‐migraine drugs or as risk factors for migraine chronification. Methods Genotyping was conducted retrospectively by real‐time polymerase chain reaction allelic discrimination assay in 219 patients with MwoA and 130 with MOH in whom migraine was the primary headache type. Gene variants association was evaluated by logistic regression analysis adjusted by confounding factors. The threshold of statistical significance was set according to the total number of polymorphisms analyzed in the current study and in previous publications arising from overlapping datasets. Results No evidence of association was found between the three polymorphisms tested and triptan response in MwoA patients. Conversely, carriers of RAMP1 rs7590387GG displayed a lower risk of episodic migraine transformation into MOH (vs C allele carriers, odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.13‐0.57, P = 0.0002; threshold of significance set at P < 0.0029). When genotype distribution for RAMP1 rs7590387 was compared between healthy controls (n = 209) and MOH patients, carriers of rs7590387GG were found at lower risk of developing MOH (OR: 0.43, 95%CI: 0.22‐0.85, P = 0.011). Conclusion These results suggest that RAMP1 rs7590387 may have a role in the transformation of episodic migraine into MOH.